| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Dec'17 |
|---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | ||||||||
106,336 | 46,928 | 68,809 | 82,810 | 82,629 | 71,976 | 69,663 | 285,518 | 45,555 |
Restricted cash | ||||||||
- | - | - | - | - | - | - | 263 | 105 |
Short-term investments | ||||||||
97,870 | 186,452 | 189,936 | 204,637 | 243,904 | 235,328 | 268,200 | 73,672 | - |
Prepaid expenses and other current assets | ||||||||
8,849 | 8,247 | 9,595 | 9,011 | 8,423 | 6,446 | 3,665 | 4,416 | 1,444 |
Total current assets | ||||||||
213,055 | 241,627 | 268,340 | 296,458 | 334,956 | 313,750 | 341,528 | 363,869 | 47,104 |
Property and equipment, net | ||||||||
5,804 | 6,398 | 6,409 | 6,359 | 6,190 | 6,356 | 2,360 | 350 | 125 |
Operating lease right-of-use assets | ||||||||
1,629 | 1,927 | 2,218 | 2,503 | 3,347 | - | - | - | - |
Restricted cash | ||||||||
210 | 210 | 210 | 210 | 210 | 210 | 210 | 210 | - |
Deferred offering costs | ||||||||
- | - | - | - | - | 433 | - | - | 25 |
Deferred tax assets | ||||||||
5,410 | 4,372 | 4,628 | 2,607 | 1,456 | 1,216 | 1,173 | 700 | 238 |
Advanced clinical payments | ||||||||
- | - | - | - | - | - | 1,830 | - | - |
Total assets | ||||||||
226,108 | 254,534 | 281,805 | 308,137 | 346,159 | 321,965 | 347,101 | 365,129 | 47,492 |
Liabilities and Shareholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | ||||||||
4,274 | 5,693 | 6,440 | 9,338 | 6,890 | 10,918 | 4,668 | 561 | 1,218 |
Accrued expenses | ||||||||
13,379 | 20,415 | 19,360 | 19,179 | 15,618 | 16,418 | 13,353 | 12,583 | 6,212 |
Accrued milestones | ||||||||
- | - | 150 | - | 13,000 | 15,000 | 10,000 | 10,000 | 10,000 |
Operating lease liabilities | ||||||||
1,689 | 1,697 | 1,610 | 1,496 | 1,384 | - | - | - | - |
Other current liabilities | ||||||||
- | 25 | - | 165 | - | 218 | - | - | - |
Total current liabilities | ||||||||
19,342 | 27,830 | 27,560 | 30,178 | 36,892 | 42,554 | 28,021 | 23,144 | 17,430 |
Non-current liabilities: | ||||||||
Non-current operating lease liabilities | ||||||||
551 | 955 | 1,391 | 1,819 | 2,239 | - | - | - | - |
Other long-term liabilities | ||||||||
381 | 326 | 943 | 943 | 509 | 144 | - | - | - |
Deferred rent | ||||||||
- | - | - | - | - | - | 167 | 186 | - |
Total liabilities | ||||||||
20,274 | 29,111 | 29,894 | 32,940 | 39,640 | 42,698 | 28,188 | 23,330 | 17,430 |
Commitments and contingencies (Note 12) | ||||||||
- | - | - | - | - | - | 0 | 0 | - |
Convertible preferred shares (Series A, B and C), $0.000273235 par value; 0 shares and 22,885,492 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively; aggregate liquidation preference of $0 and $120,000 as of December 31, 2018 and December 31, 2017, respectively; | ||||||||
- | - | - | - | - | - | - | - | 119,770 |
Shareholders’ equity: | ||||||||
Additional paid-in capital | ||||||||
588,090 | 581,467 | 576,129 | 572,318 | 566,542 | 473,483 | 470,600 | 469,018 | 1,289 |
Accumulated other comprehensive income | ||||||||
240 | 33 | 62 | 101 | 8 | -4 | -55 | 7 | - |
Accumulated deficit | ||||||||
-382,511 | -356,092 | -324,295 | -297,237 | -260,046 | -194,225 | -151,645 | -127,239 | -90,998 |
Total shareholders’ equity | ||||||||
205,834 | 225,423 | 251,911 | 275,197 | 306,519 | 279,267 | 318,913 | 341,799 | -89,708 |
Total liabilities and shareholders’ equity | ||||||||
226,108 | 254,534 | 281,805 | 308,137 | 346,159 | 321,965 | 347,101 | 365,129 | 47,492 |
Class A common shares | ||||||||
Common stock value | ||||||||
6 | 6 | 6 | 6 | 6 | 4 | - | - | - |
Class B common shares | ||||||||
Common stock value | ||||||||
1 | 1 | 1 | 1 | 1 | 1 | - | - | 1 |
Class A1 common shares | ||||||||
Common stock value | ||||||||
4 | 4 | 4 | 4 | 4 | 4 | - | - | - |
Class B1 common shares | ||||||||
Common stock value | ||||||||
4 | 4 | 4 | 4 | 4 | 4 | - | - | - |